非小细胞肺癌组织Survivin和p53蛋白表达临床意义的探讨

Expression and clinical significances of Survivin and p53 in non-small cell lung cancer

目的：探讨Survivin和p53蛋白在非小细胞肺癌（NSCLC）组织中的表达及其临床意义。方法：采用免疫组化SP法检测60例NSCLC和10例肺良性病变组织中Survivin和p53蛋白的表达。结果：NSCLC组织中Survivin蛋白阳性表达率为61．6％，明显高于正常对照组的0，χ^2=13．08，P=0．000。Survivin蛋白在临床Ⅲ～Ⅳ期的阳性表达率为77．1％，显著高于Ⅰ～Ⅱ期的40．0％，χ^2=8．511，P=0．004；而与性别、年龄以及病理类型等无明显关系，P〉0．05。NSCLC组织中p53蛋白阳性表达率为56．7％，明显高于正常对照组的0，χ^2=11．02，P=0．001。p53蛋白在临床Ⅲ～Ⅳ期的阳性表达率为71．4％，显著高于Ⅰ～Ⅱ期的36．0％，χ^2=7．454，P=0．006；而与性别、年龄以及病理类型等无明显关系，P〉0．05。结论：联合检测Survivin和p53蛋白可提高肺癌的早期诊断率，对判断病情及预后有重要临床意义。

OBJECTIVE：To investigate the function of Survivin and p53 in non-small cell lung cancer （NSCLC）. METHODS： The expression of Survivin and p53 was evaluated in 60 specimens of NSCLC and 10 specimens benign lung tissues by immunohistochemistry SP method. RESULTS： The positive rate of Survivin in lung cancer （61.6 %） was significantly higher than that of Survivin in benign tissues （0, χ^2 = 13.08, P = 0. 000）. The positive rate of Survivin in clinical stage Ⅲ -Ⅳ lung cancer （77. 1%） was significantly higher than that stage of Ⅰ - Ⅱ （40.0%）, χ^2=8.511,P=0.004. The positive rate of p53 in NSCLC （56. 7%）,was significantly higher than that of p53 in benign tissues （0, χ^2= 11.02,P=0. 001）. The positive rate of p53 in clinical stage Ⅲ -Ⅳ NSCLC （71.4%） was significantly higher than that stage of Ⅰ - Ⅱ （36.0%, χ^2 =7. 454, P= 0. 006）. Neighter Survivin nor p53 was correlated with sex, age and pathology types （P〈0.05）. CONCLUSION： The Survivin and mutant p53 gene may participate in lung carcinogenesis and development of lung cancer, and it can be identified as a marker to diagnosis and evaluate prognosis of lung cancinoma.